Metabonomic profiling of diet-induced hyperlipidaemia in a rat model

Biomarkers

Volumn 15, Issue 3, 2010, Pages 205-216

  Zhang, Qi ^a,b   Wang, Guangji ^b   A, Jiye ^b   Ma, Bo ^a,b   Dua, Yu ^a   Zhu, Lingling ^a   Wu, Di ^c  

^a NANJING TECH UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

Early diagnosis; GC MS; Hyperlipidaemia; Metabonomics; Partial least squares discriminant analysis; Principal component analysis

Indexed keywords

3 HYDROXYBUTYRIC ACID; ALANINE; ARACHIDONIC ACID; ASPARTIC ACID; BIOLOGICAL MARKER; BUTYRIC ACID; CHOLESTEROL; CREATININE; GLUCOSE; GLUTAMINE; GLYCINE; INOSITOL; ISOCITRIC ACID; ISOLEUCINE; LYSINE; MALTOSE; OCTADECADIENOIC ACID; PHENYLALANINE; PROLINE; PROPIONIC ACID; RIBOSE; SERINE; SHORT CHAIN FATTY ACID; THREONINE; TYROSINE; UNCLASSIFIED DRUG; UREA; VALINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CARDIOVASCULAR RISK; CONTROLLED STUDY; EARLY DIAGNOSIS; HYPERLIPIDEMIA; LIPID DIET; MALE; MASS FRAGMENTOGRAPHY; METABOLOMICS; MULTIVARIATE ANALYSIS; NONHUMAN; PATHOPHYSIOLOGY; PRINCIPAL COMPONENT ANALYSIS; PROTEIN ANALYSIS; RAT; SPRAGUE DAWLEY RAT;

ANIMAL FEED; ANIMALS; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HYPERLIPIDEMIAS; LIPIDS; MALE; METABOLOMICS; MULTIVARIATE ANALYSIS; RATS; RATS, SPRAGUE-DAWLEY; REPRODUCIBILITY OF RESULTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

ANIMALIA; RATTUS;

EID: 77951677264     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/13547500903419049     Document Type: Article

References (31)

1. A J, Trygg J, Gullberg J, Johansson AI, Jonsson P, Antti H, Marklund SL, Moritz T. (2005). Extraction and GC/MS analysis of the human blood plasma metabolome. Anal Chem 77:8086-8094
2. Alwaili K, Alrasadi K, Awan Z, Genest J. (2009). Approach to the diagnosis and management of lipoprotein disorders. Curr Opin Endocrinol Diabetes Obes 16:132-140
3. Denkert C.(2008). (Molecular profling and predictive signatures. Biomarker analysis in ovarian cancer). Pathologe 29 (Suppl. 2):168-171
4. Eriksson L, Antti H, Gottfries J, Holmes E, Johansson E, Lindgren F, Long I, Lundstedt T, Trygg J, Wold S. (2004). Using chemometrics for navigating in the large data sets of genomics, proteomics, and metabonomics (gpm). Anal Bioanal Chem 380:419-429
5. Eriksson L, Johansson E, Kettaneh-Wold N, Wold S. (2001). Multi-and Megavariate Data Analysis principles and Applications. Umeå: Umetrics Academy.
6. Giovane A, Balestrieri A, Napoli C. (2008). New insights into cardiovascular and lipid metabolomics. J Cell Biochem 105:648-654
7. Gof DC Jr, Bertoni AG, Kramer H, Bonds D, Blumenthal RS, Tsai MY, Psaty BM. (2006). Dyslipidemia prevalence, treatment, and control in the Multi-Ethnic Study of Atherosclerosis (MESA): gender, ethnicity, and coronary artery calcium. Circulation 113:647-656
8. Gowda GA, Zhang S, Gu H, Asiago V, Shanaiah N, Raftery D. (2008). Metabolomics-based methods for early disease diagnostics. Expert Rev Mol Diagn 8:617-633
9. Grifn JL. (2003). Metabonomics: NMR spectroscopy and pattern recognition analysis of body fuids and tissues for characterisation of xenobiotic toxicity and disease diagnosis. Curr Opin Chem Biol 7:648-654
10. Holmes E, Wilson ID, Nicholson JK. (2008). Metabolic phenotyping in health and disease. Cell 134:714-717
11. Jonsson P, Bruce SJ, Moritz T, Trygg J, Sjostrom M, Plumb R, Granger J, Maibaum E, Nicholson JK, Holmes E and others. (2005a). Extraction, interpretation and validation of information for comparing samples in metabolic LC/MS data sets. Analyst 130:701-707
12. Jonsson P, Johansson AI, Gullberg J, Trygg J, A J, Grung B, Marklund S, Sjostrom M, Antti H, Moritz T. (2005b). High-throughput data analysis for detecting and identifying diferences between samples in GC/MS-based metabolomic analyses. Anal Chem 77:5635-5642
13. Khaitovich P, Lockstone HE, Wayland MT, Tsang TM, Jayatilaka SD, Guo AJ, Zhou J, Somel M, Harris LW, Holmes E and others. (2008). Metabolic changes in schizophrenia and human brain evolution. Genome Biol 9:R124.
14. Lahoz C, Mostaza JM. (2007). (Atherosclerosis as a systemic disease). Rev Esp Cardiol 60:184-195
15. LaRosa JC. (2001). Prevention and treatment of coronary heart disease: who benefts? Circulation 104:1688-1692
16. Lewis GD, Asnani A, Gerszten RE. (2008). Application of metabolomics to cardiovascular biomarker and pathway discovery. J Am Coll Cardiol 52:117-123
17. Lindon JC, Holmes E, Bollard ME, Stanley EG, Nicholson JK. (2004a). Metabonomics technologies and their applications in physiological monitoring, drug safety assessment and disease diagnosis. Biomarkers 9:1-31.
18. Lindon JC, Holmes E, Nicholson JK. (2004b). Metabonomics and its role in drug development and disease diagnosis. Expert Rev Mol Diagn 4:189-199
19. Lindon JC, Holmes E, Nicholson JK. (2004c). Metabonomics: systems biology in pharmaceutical research and development. Curr Opin Mol Ter 6:265-272
20. Nagaraj NS. (2009). Evolving 'omics' technologies for diagnostics of head and neck cancer. Brief Funct Genomic Proteomic 8:49-59.
21. Nicholson JK, Holmes E, Elliott P. (2008). Te metabolome-wide association study: a new look at human disease risk factors. J Proteome Res 7:3637-3638
22. Nicholson JK, Lindon JC. (2008). Systems biology: metabonomics. Nature 455:1054-1056
23. Nordstrom A, Lewensohn R. (2009). Metabolomics: moving to the clinic. J Neuroimmune Pharmacol [April 28: Epub ahead of print.]
24. O'Keefe JH, Bell DS. (2007). Postprandial hyperglycemia/hyperlipi-demia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 100:899-904.
25. Raal FJ. (2009). Pathogenesis and management of the dyslipidemia of the metabolic syndrome. Metab Syndr Relat Disord 7:83-88
26. Rosenson RS. (2008). Biomarkers, atherosclerosis and cardiovascular events. Expert Rev Cardiovasc Ter 6:619-622
27. Spratlin JL, Serkova NJ, Eckhardt SG. (2009). Clinical applications of metabolomics in oncology: a review. Clin Cancer Res 15:431-440
28. Tannock LR. (2008). Advances in the management of hyperlipi-demia-induced atherosclerosis. Expert Rev Cardiovasc Ter 6:369-383
29. Trygg J, Holmes E, Lundstedt T. (2007). Chemometrics in metabonom-ics. J Proteome Res 6:469-479
30. Wishart DS, Tzur D, Knox C, Eisner R, Guo AC, Young N, Cheng D, Jewell K, Arndt D, Sawhney S and others. (2007). HMDB: the Human Metabolome Database. Nucleic Acids Res 35:D521-6.
31. Xu S-Y, Bian R-L, Chen X. (2003). Chapter 8: Methodology of pharmacology experiments in cardiovascular systems. In: Methodology of Pharmacology Experiments, 3rd edn. Beijing: People's Medical Publishing House. p. 1189-1296